TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Free Fatty Acids (FFA, mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin (mcU/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglycerides (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidation of palmitate (mass spectroscopy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overt UGI bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relief of Post Traumatic Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity and specificity of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Parent Smokers Who Enrolled in Quitline
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HOMA score decrease below 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diameter of the internal jugular vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cross-sectional area of the internal jugular vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Position of the internal jugular vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Verbal Memory Composite
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3-year local control ratio of the treated lung area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Amelioration of opacity of white spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality at 4 week
Endpoint domain: Mortality/survival
Primary endpoint: mortality at week 24
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Maximum Voluntary Ventilation (MVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Endogenous serum ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fibro-scan score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Liver Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Tumor Response (Overall Response Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cheetah ease of flap lift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surface quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of opaque bubble layer (OBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene transcript expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS pathology involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Predictive value of early serum trough concentrations of brodalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of early anti-drug antibodies of brodalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of a therapeutic window of brodalumab in psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in the Total Improvement Score (TIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Preferred injection method
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Degree of psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive organ failure
Endpoint domain: Mortality/survival
Primary endpoint: Fetal Growth Restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score of Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of the TMJ Fibrocartilage layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuity of the TMJ FC layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the TMJ fibrocartilage layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive Serum Antibodies to Ranibizumab at Month 12 and Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Technical success of perivascular injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: uncorrected distant visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OZ439 AUC(0-168 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Piperaquine Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Piperaquine AUC(0-168 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-reported Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Genital tract HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety: irritation and vaginal epithelial disruption
Endpoint domain: Adverse events/effects
Primary endpoint: Cervical length changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Androgens changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Participant-generated sensory ratings of consumed samples
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety evaluation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Esthetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fluorescence intensity of tumoral lesions, scars and healthy tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: operation mortality
Endpoint domain: Mortality/survival
Primary endpoint: paO2/FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of N. gonorrhoeae genetic markers for antimicrobial resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Death censored allograft failure
Endpoint domain: Mortality/survival
Primary endpoint: Cortical Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection rate for cancer or advanced adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with AKP decline more than 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25-hydroxyvitamin D Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort A
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Local and Systemic Solicited Adverse Events, Cohort A
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort B
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Local and Systemic Solicited Adverse Events, Cohort B
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and Intensity of Local and Systemic Solicited Adverse Events, Cohort C
Endpoint domain: Adverse events/effects
Primary endpoint: Center of Epidemiological Studies-Depression scale (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Apathy Inventory (AI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Durable phlebotomy-free complete hematological response (CHR) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in cerebral oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in somatic oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of surgical methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical remission after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of identifying the intralaminar space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Who Achieved Anesthesia Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluate Any Adverse Effects Associated With the Iontophoresis System
Endpoint domain: Adverse events/effects
Primary endpoint: Constant-Murley Shoulder Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Donors Requiring Second Collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Local and systemic safety
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of plasma budesonide and formoterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of plasma budesonide and formoterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first variceal bleed
Endpoint domain: Mortality/survival
Primary endpoint: Splanchnic glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in knowledge measurements in diabetes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma carotenoids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in platelet activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of mature oocytes recruited
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline in plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of MK6186 measured by number of clinical and laboratory adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Eyelid measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Evaluated for Vaccine Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increase in disclosure of HIV status to sex partner
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MRI biomarkers for fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: VAS Measurement of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients who initiated statins
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Type of non-surgical complication
Endpoint domain: Adverse events/effects
Primary endpoint: Daily number of steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peer Violence Involvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pulse Wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Finnegan Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Complete Response (pCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antro-posterior stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Over All Stability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mediolateral Stability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response (CR) and Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knowledge about normal bowel functioning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analogue Scale Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Acceptability Rate of the Program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Satisfaction With the Program
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Child occupational performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bioavailability of Envarsus® compared to tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance modulation on attention and emotional paradigms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre- and postprandial glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pre-transplant insulin secretion (GSIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post-transplant glucagon secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma IL-33 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at 90 Days
Endpoint domain: Mortality/survival
Primary endpoint: detection rate of sentinel lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: positive rate of sentinel lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PLR response amplitude and latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of primary rectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Histologically confirmed complete resection rate (R0 rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: relationship closeness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: sexual intimacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of Serious Adverse Reactions (SAR)
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom severity-abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in epistaxis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hopkins Symptom Checklist-25
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaginal Pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients with a blood pressure drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biochemically-confirmed 7-Day Point-Prevalence Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Labs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioisotope clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Serum Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cavg of Serum Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC0-t of Serum Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of hospital re-admissions due to COPD exacerbations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Death or long-term major neurodevelopmental disability
Endpoint domain: Mortality/survival
Primary endpoint: Functional Connectivity Between Amygdala-hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite of Limb Salvage and Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Freedom From Major Adverse Limb Event + Peri-Operative Death Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Eyes Grade 3 or Higher SLF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the expression of the PAM50 proliferation signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic response to analgesic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma concentrations of leucinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cormack-Lehane Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newly detected cases of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participation in work and school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: MIRECC GAF occupational, social and symptom functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hepatic ATZ Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macroscopic evaluation of tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Meeting Post-vaccination Antibody Response Rates to Hepatitis B and Haemophilus Influenzae Type B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-vaccination Geometric Mean Titres (GMT) to Pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of cases achieving level I and II remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting one or More AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting one or More SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting one or More ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Assessed for Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Positivity rate of CMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post craniotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problems reported on the EQ-5D dimensions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EQ-VAS value
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Specific Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PROMIS physical function scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Defense and Veterans Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum effective dose of inhaled azacitidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of reduction/stabilisation of tumour size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete Response and Very Good Partial Response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1c for patients with Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Regional bronchial recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Regional bronchial dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Regional alveolar recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes